GlassScriptPhysician profile
Sridevi Allu
NPI 1912137365
$6,884.66
in general payments reported to CMS, 2019-2025
39 companies · $479 in 2025
The $479 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,096 · 2020: $1,113 · 2021: $1,313 · 2022: $1,177 · 2023: $855 · 2024: $851 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,185.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,839.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $612.54 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $567.75 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $418.87 | 2019-2025 | Airsupra, Farxiga |
| Abbvie INC. | $355.36 | 2019-2025 | Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.80 | 2019-2025 | Jardiance, Synjardy |
| Pfizer INC. | $251.10 | 2019-2024 | |
| Bausch Health US, LLC | $215.19 | 2019-2023 | Wellbutrin, Aplenzin |
| Astellas Pharma US INC | $213.01 | 2019-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $205.33 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $172.62 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.13 | 2019-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $157.84 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $153.71 | 2019-2022 | |
| Amarin Pharma, INC. | $145.04 | 2019-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $121.71 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $116.37 | 2019-2024 | |
| Esperion Therapeutics, INC. | $94.97 | 2020-2025 | Nexletol |
| Glaxosmithkline, LLC. | $78.43 | 2020-2025 | Shingrix, Arexvy |
| Medtronic, INC. | $73.28 | 2023-2025 | Intellis Adaptivestim, Vectris Surescan, Inceptiv |
| Daiichi Sankyo INC. | $72.45 | 2020-2021 | |
| Allergan, INC. | $51.34 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.95 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.43 | 2022 | |
| Exact Sciences Corporation | $44.49 | 2023-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $37.31 | 2025 | Auvelity |
| Lundbeck LLC | $36.00 | 2024-2025 | Rexulti |
| Dexcom, INC. | $34.89 | 2024-2025 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $34.17 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $29.94 | 2023-2025 | Evkeeza |
| Currax Pharmaceuticals LLC | $28.04 | 2022-2025 | Contrave |
| Abbott Laboratories | $21.41 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $19.34 | 2021 | |
| Eisai INC. | $18.56 | 2024 | |
| Sumitomo Pharma America, INC. | $16.65 | 2024 | Gemtesa |
| Seqirus USA INC | $12.77 | 2021 | |
| Shire North American Group INC | $11.92 | 2019 | |
| Sanofi Pasteur INC. | $11.62 | 2020 | |
| Medtronic USA, INC. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sridevi Allu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.